trastuzumab emtansine
Ligand Summary
Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
ChEMBL: CHEMBL1743082
DrugCentral: 4990
LyCHI: trastuzumab emtansine
Target Activities
10 Activities
Items per page:
1 – 10 of 10
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
ANTIBODY BINDING | ||||||